R&D Pipeline

R&D Pipeline Pipeline (2021-2030)

Pipeline (2021-2030)

Respiratory - Discovery (17)

Modality Indication Targets Stage Company Project No. Detail
1 Development of a first-in-class therapeutic antibody lead targeting GTC-D1 for pulmonary fibrosis
Antibody IPF GTC-D1 Hit Good T cells, Inc. RS-2025-25455100
2 ASO-Based Therapeutics Targeting ATX for Pulmonary Fibrosis
Gene & Nucleic acids Pulmonary fibrosis ATX (autotaxin) Hit Sookmyung Women's University RS-2025-02213647
3 Development of antibodies to induce lung regeneration for the treatment of emphysema
Antibody Pulmonary emphysema Robo1 Hit Asan Medical Center HN21C0202
4 Development of therapeutic fully human monoclonal antibody FBPF-11X as lead compound for pulmonary fibrosis
Antibody Pulmonary fibrosis FBFP-101-T Lead FNCT Biotech HN22C0683
5
Other-Bio. Bronchopulmonary Dysplasia(BPD) Ago2 Lead Samsung Medical Center HN22C0414
6 Derivation of lead candidates for idiopathic 
pulmonary fibrosis treatment through inhalant 
optimization of integrin selective binding peptide
rProtein IPF Integrin αVβ-3,5,6 Lead NEXEL HN22C0012
7 Development of drug candidate against respiratory infection using Foxj1 as a target
Small molecules Pneumonia Foxj1 Lead Chonnam National University HN21C0513
8 Elicitation of lead compounds for the treatment of chronic obstructive pulmonary disease targeting leucotriene B4 receptor BLT2
Small molecules COPD BLT2 Lead Korea university HN21C0996
9 Study on lead generation for IPF (idiopathic pulmonary fibrosis) drug based on AI platform
Small molecules IPF CHIT1 Lead INNOVO Therapeutics HN21C0205
10 Development of small-molecule asthma drug that inhibits the binding of IL-33 to its receptor
Small molecules Asthma IL-33 Lead AZCURIS HN21C0187
11 Development of a Pre-clinical Candidate for Progressive Fibrosing Interstitial Lung Disease Targeting gp130 (an IL-6 Family Cytokine) Inhibition
Small molecules Auto-immune Diseases & Progressive Fibrosing Interstitial Lung Disease gp130 Candidate Primo Thera CO., Ltd. RS-2025-25452684
12 Development of a Lung-Selective RNA Therapeutic Candidate for lung fibrosis
Gene & Nucleic acids IPF **** Candidate Samyang Biopharm RS-2025-25448962
13 Development of Selective PDE-4B Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Small molecules Idiopathic pulmonary fibrosis PDE-4B Candidate Jeil Pharmaceutical RS-2025-02213196
14 Development of CSF3 targeted Pre-clinical Candidate Human Monoclonal Antibody FB-101 for Pulmonary Fibrosis
Antibody Idiopathic Pulmonary Fibrosis CSF3 Candidate FNCT Biotech, Inc. RS-2024-00461975
15 Discovery of a novel small-molecule drug candidate targeting IL-33
Small molecules Asthma IL-33 Candidate Azcuris Co., Ltd. RS-2024-00333140
16 Discovery of a ‘First.In.Class’ New Drug for IPF Treatment
Small molecules Idiopathic pulmonary fibrosis ARPC2 Candidate SapiensBio.Inc RS-2023-00283815
17 ATB-610: Small molecule developing as a inhaler with reducing toxicity by inhibiting ALK5 selectively for IPF treatment
Small molecules IPF ALK5 Candidate Autotelic Bio RS-2022-00165740
BACK